These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8754440)

  • 21. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.
    Maier-Redelsperger M; de Montalembert M; Flahault A; Neonato MG; Ducrocq R; Masson MP; Girot R; Elion J
    Blood; 1998 Jun; 91(12):4472-9. PubMed ID: 9616141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K; Smith-Whitley K
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease.
    Fung EB; Barden EM; Kawchak DA; Zemel BS; Ohene-Frempong K; Stallings VA
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):604-8. PubMed ID: 11902305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Moore RD; Charache S; Terrin ML; Barton FB; Ballas SK
    Am J Hematol; 2000 May; 64(1):26-31. PubMed ID: 10815784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
    Luchtman-Jones L; Pressel S; Hilliard L; Brown RC; Smith MG; Thompson AA; Lee MT; Rothman J; Rogers ZR; Owen W; Imran H; Thornburg C; Kwiatkowski JL; Aygun B; Nelson S; Roberts C; Gauger C; Piccone C; Kalfa T; Alvarez O; Hassell K; Davis BR; Ware RE
    Am J Hematol; 2016 Feb; 91(2):238-42. PubMed ID: 26615793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
    Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrapatient variability in fetal hemoglobin measurements over time in sickle cell patients not on fetal hemoglobin inducing agents.
    Knapp E; Cohen H; Kutlar A; Ghalie R; Manwani D
    Am J Hematol; 2016 Mar; 91(3):E11-2. PubMed ID: 26661045
    [No Abstract]   [Full Text] [Related]  

  • 28. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
    Patel DK; Mashon RS; Patel S; Das BS; Purohit P; Bishwal SC
    Hemoglobin; 2012; 36(5):409-20. PubMed ID: 22881992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxyurea therapy for sickle cell anemia.
    McGann PT; Ware RE
    Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mortality in sickle cell patients on hydroxyurea therapy.
    Bakanay SM; Dainer E; Clair B; Adekile A; Daitch L; Wells L; Holley L; Smith D; Kutlar A
    Blood; 2005 Jan; 105(2):545-7. PubMed ID: 15454485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: a Portuguese hospital study.
    Braga LB; Ferreira AC; Guimarães M; Nazário C; Pacheco P; Miranda A; Picanço I; Seixas T; Rosado L; Amaral JM
    Hemoglobin; 2005; 29(3):171-80. PubMed ID: 16114180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea for sickle cell anemia.
    Naina HV; Harris S
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
    [No Abstract]   [Full Text] [Related]  

  • 33. Sickle cell paths converge on hydroxyurea.
    Platt OS
    Nat Med; 1995 Apr; 1(4):307-8. PubMed ID: 7585059
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of hydroxyurea in the management of sickle cell disease.
    Davies SC; Gilmore A
    Blood Rev; 2003 Jun; 17(2):99-109. PubMed ID: 12642122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW; Kennedy LD
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxyurea in children: present and future.
    Vichinsky EP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in quality of life between pediatric sickle cell patients who used hydroxyurea and those who did not.
    Nwenyi E; Leafman J; Mathieson K; Ezeobah N
    Int J Health Care Qual Assur; 2014; 27(6):468-81. PubMed ID: 25115050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea and sickle cell disease: a chance for every patient.
    Weiner DL; Brugnara C
    JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739
    [No Abstract]   [Full Text] [Related]  

  • 39. Hydroxyurea: Analytical techniques and quantitative analysis.
    Marahatta A; Ware RE
    Blood Cells Mol Dis; 2017 Sep; 67():135-142. PubMed ID: 28847416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response.
    Sadaf A; Quinn CT; Korpik JB; Pfeiffer A; Reynaud M; Niss O; Malik P; Ware RE; Kalfa TA; McGann PT
    Blood Cells Mol Dis; 2021 Sep; 90():102576. PubMed ID: 34020272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.